1. Elevated platelet-leukocyte complexes are associated with, but dispensable for myocardial ischemia-reperfusion injury
- Author
-
Christopher Starz, Carmen Härdtner, Maximilian Mauler, Bianca Dufner, Natalie Hoppe, Katja Krebs, Carolin Anna Ehlert, Julian Merz, Timo Heidt, Peter Stachon, Dennis Wolf, Christoph Bode, Constantin von zur Muehlen, Wolfgang Rottbauer, Meinrad Gawaz, Daniel Duerschmied, Florian Leuschner, Oliver Borst, Dirk Westermann, and Ingo Hilgendorf
- Subjects
Mice ,P-Selectin ,Physiology ,Physiology (medical) ,Reperfusion Injury ,Leukocytes ,Myocardial Infarction ,Myocardial Ischemia ,Animals ,Myocardial Reperfusion Injury ,Cardiology and Cardiovascular Medicine - Abstract
Aims P-selectin is an activatable adhesion molecule on platelets promoting platelet aggregation, and platelet–leukocyte complex (PLC) formation. Increased numbers of PLC are circulating in the blood of patients shortly after acute myocardial infarction and predict adverse outcomes. These correlations led to speculations about whether PLC may represent novel therapeutic targets. We therefore set out to elucidate the pathomechanistic relevance of PLC in myocardial ischemia and reperfusion injury. Methods and results By generating P-selectin deficient bone marrow chimeric mice, the post-myocardial infarction surge in PLC numbers in blood was prevented. Yet, intravital microscopy, flow cytometry and immunohistochemical staining, echocardiography, and gene expression profiling showed unequivocally that leukocyte adhesion to the vessel wall, leukocyte infiltration, and myocardial damage post-infarction were not altered in response to the lack in PLC. Conclusion We conclude that myocardial infarction associated sterile inflammation triggers PLC formation, reminiscent of conserved immunothrombotic responses, but without PLC influencing myocardial ischemia and reperfusion injury in return. Our experimental data do not support a therapeutic concept of selectively targeting PLC formation in myocardial infarction.
- Published
- 2022